Scientific deep-dive

Low-Carb vs Low-Fat: Which Reduces Visceral Fat More?

Randomized trials that imaged or estimated visceral fat give low-carb a small edge in DIETFITS, but long-term pooled data show little difference. What the depot data, genotype analyses and lipid trade-offs mean.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
7 min read·12 citations

Low-carb has a small measured edge over low-fat for visceral fat in the largest trial reviewed here, but the wider evidence does not make it a clear winner. In DIETFITS, adults on a healthy low-carbohydrate diet lost an estimated 6.3 cm² more visceral fat at 12 months than adults on a healthy low-fat diet (95% CI 0.6 to 12), in an analysis of 449 of the 609 people randomized[1]. A 2026 meta-analysis of trials lasting at least a year found no difference in visceral fat across diets, “with only few exceptions”[4].

About this article

Most diet comparisons report weight. This one looks at fat depots, using trials and reviews that imaged or estimated visceral fat, the deep fat around the abdominal organs. The exceptions are a genotype analysis that measured weight only and a lipid trial whose abstract reports no visceral fat data, and both are described as such where they appear.

What DIETFITS showed when visceral fat was estimated

DIETFITS randomized 609 adults aged 18 to 50 without diabetes, with a BMI of 28 to 40, to a healthy low-fat or healthy low-carbohydrate diet for 12 months[2]. Its primary outcome was weight, and the gap there was not statistically significant: -5.3 kg on low-fat and -6.0 kg on low-carb (mean between-group difference 0.7 kg, 95% CI -0.2 to 1.6)[2].

A later analysis used dual-energy X-ray absorptiometry (DXA) scans to estimate visceral fat at baseline, 6 and 12 months. Low-carb came out ahead by 10.6 cm² at 6 months (95% CI 5 to 16.2) and by 6.3 cm² at 12 months (95% CI 0.6 to 12)[1]. Three details shape how much weight to put on that result:

  • The gap narrowed with time. The lower bound of the 12-month interval sits close to zero[1]. Visceral loss relative to subcutaneous loss favored low-carb at 6 months only[1].
  • It was estimated from DXA. The authors estimated visceral fat from DXA rather than measuring it with CT or MRI, and the analysis covers 449 participants rather than everyone randomized[1].
  • “Low-carb” was moderate by 12 months. Average intake at that point was 30% of energy from carbohydrate on low-carb and 48% on low-fat, with fat at 45% and 29%[2]. These numbers describe a real-world, counseled diet, far from strict ketosis.

Men had a larger low-carb visceral response than women[1]. The abstract does not give a separate figure for each sex, so we can’t say how large that difference was.

Imaging trials point in different directions

Smaller trials that measured visceral fat range from no difference to a very large one, and their designs explain part of the spread. The table summarizes DIETFITS[1], CENTRAL[3], a Norwegian trial in men[6], a trial in older adults[7], a German trial focused on liver fat[8] and a Chinese walnut-based trial[9].

Randomized trials comparing lower-carbohydrate and lower-fat diets on visceral fat
TrialParticipantsLengthVisceral fat methodVisceral fat result
DIETFITS (Follis 2026)449 analyzed of 609 randomized; mean age 39; 60% women12 monthsEstimated from DXAFavored low-carb: 10.6 cm² at 6 months, 6.3 cm² at 12 months
CENTRAL (Gepner 2018)278 sedentary adults; 89% men; abdominal obesity or dyslipidemia18 monthsMRIVisceral fat fell 22% overall; the abstract names diet advantages in other depots, not visceral
Veum 201746 men aged 30 to 5012 weeksCTSimilar on both diets: 1350 to 1650 cm³ lost
Goss 202034 adults aged 60 to 75 with obesity8 weeksMRI-22.8% on very low-carb vs -1.0% on low-fat
Haufe 2011170 randomized; 102 completed with liver measures6 monthsMR tomographyFell on both diets; no between-diet figure in the abstract
Dong 2026Adults with central obesity12 weeksVisceral fat areaSignificant group-by-time interaction; no significant gap between groups at 12 weeks

The Norwegian trial is the cleanest test of macronutrients alone. It matched protein and food profile, emphasized low-processed, lower-glycemic foods, and assigned men to 73% or 30% of energy from fat. Visceral fat, waist size and weight fell about equally, and the authors concluded the two patterns “did not differentially influence visceral fat”[6]. It was also short and small, and reported energy intake fell by 22% on the low-fat diet and 14% on the high-fat diet[6].

The most dramatic number comes from the trial in older adults, with visceral fat down 22.8% on a very low-carb diet and 1.0% on a low-fat diet (p < 0.001)[7]. Total fat also fell much more on very low-carb, 9.7% against 2.0%, so this was not a shift between depots at equal fat loss[7]. The trial lasted 8 weeks, enrolled 34 people, was registered retrospectively, and one author disclosed advisory roles with Virta Health and Atkins Nutritionals[7].

CENTRAL is the longest imaging trial in this group, but its comparison arm was a Mediterranean low-carbohydrate diet with 28 g of walnuts a day, so it does not isolate carbohydrate[3]. Weight loss ended up similar. The abstract reports that this diet beat low-fat for liver, pericardial and pancreatic fat, while it credits added exercise, on either diet, with more visceral loss (mean difference -6.67 cm², 95% CI -14.8 to -0.45)[3]. That figure is close to the DIETFITS 12-month diet gap in size, though this is a comparison across different trials and it stays indirect. Our review of menopause belly fat looks at the same depot question for women going through that transition, a group CENTRAL barely covered.

What the pooled analyses add

Two 2026 reviews answer related but different questions. The Nutrition Reviews meta-analysis included 23 trials of at least 12 months and found no fat-mass difference between high-fat, low-carbohydrate and low-fat, high-carbohydrate diets, and no visceral difference across diets beyond a few exceptions[4]. Most of its trials had high or unclear risk of bias, and most interventions lasted 12 months[4].

A network meta-analysis in Critical Reviews in Food Science and Nutrition ranked diets on visceral fat by P-score, a measure of relative rank rather than size of effect: intermittent fasting 0.91, very low-carbohydrate 0.84, low-fat 0.62, low-carbohydrate 0.46, calorie restriction 0.42 and moderate-carbohydrate 0.25[5]. Very low-carb was significantly more effective than moderate-carb, and all of these reduced visceral fat compared with controls[5]. So this review ranks low-fat above ordinary low-carb and below very low-carb. The abstract gives no effect sizes, so the practical gap between those ranks is unclear.

Can a gene or insulin test pick your diet?

Current evidence does not support choosing on that basis. In the DIETFITS weight analysis, neither a three-variant genotype pattern (interaction P = .20) nor insulin secretion 30 minutes after a glucose challenge (P = .47) predicted which diet worked better[2]. The visceral analysis agrees on insulin: secretion status did not modify visceral loss[1].

A 2025 secondary analysis looked at one variant, APOA2 rs5082, among participants who consistently met a saturated-fat intake criterion. People with the TT genotype lost more weight on low-carb at 3, 6 and 12 months, while C allele carriers did so only at 3 months[10]. That result concerns weight and not visceral fat, it comes from a selected subgroup, and the authors present it as a way to inform precision nutrition research. It does not establish a test anyone should buy.

Why a small difference could matter, and what it can cost

Visceral fat draws this attention because of follow-up data. In a 5- and 10-year follow-up of CENTRAL and DIRECT-PLUS reaching 366 of 381 eligible participants, each 10% loss of visceral fat during the trials was independently associated with a lower risk of type 2 diabetes (hazard ratio 0.72, 95% CI 0.54 to 0.94), despite complete weight regain[11]. Waist size and abdominal fat depots stayed partly improved, while liver fat loss did not last[11]. This is an association after the randomized phase ended, so it can’t show that a specific diet caused the benefit.

Blood lipids are the other side of the ledger. In a 24-week trial of 88 abdominally obese adults, which did not report visceral fat in its abstract, weight loss was similar, but LDL cholesterol fell on the high-carbohydrate, low-fat diet (-0.46 mmol/L) and stayed flat on the very low-carbohydrate diet (0.06 mmol/L), with 24% of people on the latter seeing a rise of at least 10%[12]. That diet also improved triglycerides and HDL more[12]. In the Norwegian trial, total and LDL cholesterol fell in the low-fat group only, and HDL rose in the high-fat group only[6]. Neither trial tells you how an individual will respond.

Where this fits if you take a GLP-1

None of the abstracts reviewed here reports results for people taking a GLP-1 medication, so the size of any diet effect on top of one is unknown. Semaglutide has its own imaging evidence, covered in our review of belly fat on semaglutide. A difference on the scale of the 6.3 cm² seen in DIETFITS[1] is not something to assume would carry over to people on medication. When appetite is low, the practical question is usually which eating pattern lets you hit your protein and calorie targets, and the macro calculation guide walks through that.

What to raise with a prescriber

  • If you are considering a very low-carb diet, ask whether to check LDL cholesterol once you are established on it, since the response varied widely between individuals in one trial[12].
  • If you take a glucose-lowering medication, ask whether any dose should change before you cut carbohydrate sharply.
  • If you have been offered a genetic test to choose a diet, ask what it would change, given that DIETFITS found no useful genotype or insulin predictor[2].
  • If you want to track visceral fat, ask whether imaging is warranted at all and how you would act on the result. Waist size is what the long-term follow-up also tracked[11].

Frequently Asked Questions

The evidence leans slightly toward low-carb in one large trial but does not settle it. DIETFITS estimated 6.3 cm² more visceral fat loss on low-carb at 12 months, while a 2026 meta-analysis of trials lasting a year or more found no difference across diets with only a few exceptions.
Some short trials suggest it can. An 8-week trial of 34 older adults found visceral fat down 22.8% on a very low-carb diet and 1.0% on low-fat, but total fat also fell far more on very low-carb. A 12-week trial in 46 men that matched protein and food quality found no visceral difference.
The main trial evidence says no useful test exists yet. DIETFITS found no significant interaction between diet and a three-variant genotype pattern or insulin secretion for weight loss, and insulin secretion did not modify visceral loss. A later analysis of one APOA2 variant measured weight only, in a selected subgroup.
These trials cannot answer that, because none of the abstracts reviewed reports results for people on a GLP-1 medication. Discuss your eating pattern with your prescriber, particularly if you take glucose-lowering medicine, and consider asking about LDL cholesterol monitoring if you plan a very low-carb diet.

References

  1. 1.Follis S, Landry MJ, Cunanan KM, Stefanick ML, Ward CP, Gardner CD. Effect of low-carbohydrate vs low-fat diet intervention on visceral fat estimated from dual energy X-ray absorptiometry in a 12-month randomized controlled trial. Int J Obes (Lond). 2026. PMID: 41436888.
  2. 2.Gardner CD, Trepanowski JF, Del Gobbo LC, Hauser ME, Rigdon J, Ioannidis JPA, Desai M, King AC. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion: The DIETFITS Randomized Clinical Trial. JAMA. 2018. PMID: 29466592.
  3. 3.Gepner Y, Shelef I, Schwarzfuchs D, et al. Effect of Distinct Lifestyle Interventions on Mobilization of Fat Storage Pools: CENTRAL Magnetic Resonance Imaging Randomized Controlled Trial. Circulation. 2018. PMID: 29142011.
  4. 4.Jabbour J, Issa Z, Jaafar T, et al. Long-Term Diets and Changes in Body Composition and Bone Mineral Density: A Systematic Review and Meta-analysis. Nutr Rev. 2026. PMID: 41689541.
  5. 5.Khalafi M, Habibi Maleki A, Ehsanifar M, et al. The efficacy of carbohydrate-restricted diets on reducing visceral and liver fat in individuals with overweight and obesity: a systematic review and pairwise and network meta-analyses. Crit Rev Food Sci Nutr. 2026. PMID: 42234546.
  6. 6.Veum VL, Laupsa-Borge J, Eng Ø, et al. Visceral adiposity and metabolic syndrome after very high-fat and low-fat isocaloric diets: a randomized controlled trial. Am J Clin Nutr. 2017. PMID: 27903520.
  7. 7.Goss AM, Gower B, Soleymani T, et al. Effects of weight loss during a very low carbohydrate diet on specific adipose tissue depots and insulin sensitivity in older adults with obesity: a randomized clinical trial. Nutr Metab (Lond). 2020. PMID: 32817749.
  8. 8.Haufe S, Engeli S, Kast P, et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology. 2011. PMID: 21400557.
  9. 9.Dong Q, Tan X, Feng P, Tian Q, Jiang Q, Wang X, Wang L. Effect of a walnut-based low carbohydrate diet on fat redistribution and visceral fat accumulation in people with central obesity: A randomized controlled trial. Asia Pac J Clin Nutr. 2026. PMID: 42815962.
  10. 10.Lai CQ, Parnell LD, Das SK, Gardner CD, Ordovás JM. Differential weight-loss responses of APOA2 genotype carriers to low-carbohydrate and low-fat diets: the DIETFITS trial. Obesity (Silver Spring). 2025. PMID: 40310284.
  11. 11.Klein H, Alufer L, Goldberg Toren DT, et al. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials. Circulation. 2026. PMID: 42227111.
  12. 12.Tay J, Brinkworth GD, Noakes M, Keogh J, Clifton PM. Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in abdominally obese subjects. J Am Coll Cardiol. 2008. PMID: 18174038.

Which Exercise Reduces Visceral Fat Most? What Network Meta-Analyses Show

HIIT tops two 2026 network analyses on visceral fat, but combined or aerobic training leads in other groups, and head-to-head trials are less convincing. Resistance training ranks last each time. Here are the rankings, doses and caveats.

7 min read

Tirzepatide Body Composition: SURMOUNT-1 & SURPASS-3 Imaging

Tirzepatide imaging evidence: SURMOUNT-1 DXA cut visceral fat ~40% with ~74% of weight lost as fat; SURPASS-3 MRI slashed liver fat. (No real SURMOUNT-MORPH.)

13 min read

Tesamorelin for Visceral (Belly) Fat: What the Evidence Shows

Tesamorelin (Egrifta) cuts visceral fat about 15-18% by CT in HIV lipodystrophy, its only FDA indication. Off-label use for general belly fat lacks registration-quality RCT evidence. Cardiometabolic angle and safety.

11 min read

Does Keto Beat Other Diets at Equal Calories? What a 2026 Meta-Analysis Found

A 2026 meta-analysis found keto diets produced slightly more weight loss than higher-carbohydrate diets at matched calorie prescriptions, with low certainty. Here is what that small gap means, plus the LDL and lean mass evidence.

8 min read

Ultra-Processed Foods and Weight: The Controlled Feeding Evidence

Controlled feeding trials link ultra-processed diets to higher calorie intake and less favorable weight change, but they are short and small, and a 2026 meta-analysis rated certainty low. Here is what each trial found and why energy density is the open question.

8 min read

Tesamorelin vs GLP-1s for Fat Loss: How Do They Compare?

Tesamorelin reduces visceral fat in HIV lipodystrophy; GLP-1 agonists drive total-body weight loss in obesity. An evidence review of mechanisms, trials, and endpoints — why they treat different fat problems.

8 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

7.1

AgelessRx

Longevity-focused GLP-1 care with microdosing and brand-name options

Read full review →

From $139/mo

4-month plan rate

Get started →
7.7

Ro

FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help

Read full review →

From $149/mo

+ required membership

Get started →
8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Read full review →

From $59/mo

+ required membership

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →